Advanced Search

Journal of Traditional Chinese Medicine >

2024 , Vol. 44 >Issue 3: 489 - 495

DOI: https://doi.org/10.19852/j.cnki.jtcm.20231204.005

Original articles

Exploring the multicomponent synergy mechanism of Zuogui Wan (左归丸) on postmenopausal osteoporosis by a systems pharmacology strategy

  • Yanchen FENG ,
  • Yali LIU ,
  • Xue DANG ,
  • Zixuan LIN ,
  • Yunke ZHANG ,
  • Zhiying CHE ,
  • Xiang LI ,
  • Xiaolong PAN ,
  • Feixiang LIU ,
  • Pan ZHENG
Expand
  • 1 Traditional Chinese Medicine (Zhong Jing) School, Henan University of Chinese Medicine, Zhengzhou 450046, China
    2 Hospital of Encephalopathy, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China
    3 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Research Units of Infectious Disease and Microecology, Chinese Academy of Medical Sciences, Hangzhou 31000, China

Received date: 2023-02-22

  Accepted date: 2023-07-14

  Online published: 2023-12-04

Supported by

National Natural Science Foundation of China: Research on Mechanism of Zuogui Wan in Treating Postmenopausal Osteoporosis by Regulating Feed-forward Loop of Oxytocin/Oxytocin Receptor Based on Transcriptome so as to Explain the Theory of “All Marrows Dominated by Brain”(82104730);Based on Protein Kinase Cθ/Nuclear Factor Kappa-B Signal Transduction Regulation, Shexiang Huangqi Compound Dropping Pills Regulate the Migration and Differentiation Mechanism of Mesenchymal Stem Cells Through the Blood-brain Barrier after Cerebral Ischemia(81974564);NThe 72nd Batch of China Postdoctoral Science Foundation(2022M721065);Central Plains Talent Program-science and Technology Innovation Leading Talent Project(224200510027)

Fold

Abstract

OBJECTIVE: To explore the multi-component synergistic mechanism of Zuogui Wan (左归丸, ZGW) in treating postmenopausal osteoporosis (PMOP).

METHODS: The main components and target genes of ZGW were screened via the Traditional Chinese Medicine Systems Pharmacology (TCMSP). In addition, the target gene sets of PMOP were derived from the GeneCards and Online Mendelian Inheritance in Man databases. The search tool for recurring instances of neighbouring genes (STRING) 11.0 software was used to analyze the interaction among intersecting genes. Cytoscape 3.6.1 software and the Matthews correlation coefficient (MCC) algorithm were used to screen the core genes. Fifty Sprague-Dawley female rats were randomly divided into the sham-operated (Sham) group and the four ovariectomized (OVX) subgroups. Rats subjected to Sham or OVX were administered with the vehicle (OVX, 1 mL water/100 g weight), 17β-estradiol (E2, 50 μg·kg-1·d-1), and lyophilized powder of ZGW at a low dose of 2.3 (ZGW-L) and high dose of 4.6 (ZGW-H) g·kg-1·d-1 for three months. The bone density and bone strength were assessed using dual-energy X-ray and three-point bending tests, respectively. Furthermore, enzyme-linked immun-osorbent assay, Hematoxylin-eosin staining, and western blot analysis were used to determine the potential pharmacological mechanisms of action of ZGW in PMOP.

RESULTS: A total of 117 active compounds of ZGW were screened from the TCMSP. Furthermore, 108 intersecting genes of drugs and diseases were identified. Using STRING software and the MCC algorithm, ten core genes, including C-X-C chemokine living 8 (CXCL8), C-C chemokine receptor type 2 (CCR2), alpha-2a active receptor (ADRA2A), melatonin receptor type 1B (MTNR1B), and amyloid-beta A4 protein (APP), were identified. The anti-osteoporosis regulation network of ZGW was constructed using the Cytoscape software. The animal experiments demonstrated that ZGW groups significantly reduced the serum levels of β-C-terminal telopeptide of type I collagen (β-CTX) and increased serum levels of bone-specific alkaline phosphatase (BALP) (P < 0.05, P < 0.01). The OVX group exhibited a significant decrease in bone mineral density and bone strength compared with the Sham group (P < 0.01). Moreover, treatment with ZGW resulted in increased trabecular thickness, improved arrangement of trabecular structure, and reduced empty bone lacunae. Furthermore, treatment with ZGW significantly increased the protein expression of CXCL8, ADRA2A, and CCR2 (P < 0.05, P < 0.01), and significantly decreased the protein expression of Runx2 (P < 0.01). Furthermore, the ZGW and E2 groups demonstrated significantly increased BMD (P < 0.05, P < 0.01), improved bone strength (P < 0.05, P < 0.01), reduced expression of CXCL8, ADRA2A, and CCR2, and increased runt-related transcription factor 2 levels in bone tissue (P < 0.05, P < 0.01) compared with the OVX group. However, there were no significant differences in MTNR1B and APP expression among the groups.

CONCLUSION: ZGW shows synergistic mechanisms in PMOP through multiple components, targets, and pathways.

Key words： osteoporosis, postmenopausal; network pharmacology; Zuogui Wan

Cite this article

Yanchen FENG , Yali LIU , Xue DANG , Zixuan LIN , Yunke ZHANG , Zhiying CHE , Xiang LI , Xiaolong PAN , Feixiang LIU , Pan ZHENG . Exploring the multicomponent synergy mechanism of Zuogui Wan (左归丸) on postmenopausal osteoporosis by a systems pharmacology strategy[J]. Journal of Traditional Chinese Medicine, 2024 , 44(3) : 489 -495 . DOI: 10.19852/j.cnki.jtcm.20231204.005

References

1. Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 2015; 386: 1147-55.
2. Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2016; 374: 254-62.
3. Si Y, Wang C, Guo Y, Xu G, Ma Y. Prevalence of osteoporosis in patients with type 2 diabetes mellitus in the Chinese mainland: a systematic review and Meta-analysis. Iran J Public Health 2019; 48: 1203-14.
4. Cosman F. Long-term treatment strategies for postmenopausal osteoporosis. Curr Opin Rheumatol 2018; 30: 420-6.
5. Le QA, Hay JW, Becker R, Wang Y. Cost-effectiveness analysis of sequential treatment of abaloparatide followed by alendronate versus teriparatide followed by alendronate in postmenopausal women with osteoporosis in the United States. Ann Pharmacother 2019; 53: 134-43.
6. Li J, Lian JW. Pharmacology of traditional Chinese medical formulae. 4th ed. Beijing: China Press of Traditional Chinese Medicine, 2016: 138-9.
7. Hu Y, Zheng S, Fan Y, Sun L. Effects of Zuogui Wan on bone metabolism and fall risk in elderly diabetic patients. An Mo Yu Kang Fu Yi Xue 2017; 8: 51-4.
8. Liu F, Tan F, Tong W, et al. Effect of Zuogui Wan on osteoporosis in ovariectomized rats through RANKL/OPG pathway mediated by β2AR. Biomed Pharmacother 2018; 103: 1052-60.
9. Kang X, Chen L, Yang S, et al. Zuogui Wan slowed senescence of bone marrow mesenchymal stem cells by suppressing Wnt/β-catenin signaling. J Ethnopharmacol 2022; 294: 115323.
10. Artero A, Artero A, Tarín JJ, Cano A. The impact of moderate wine consumption on health. Maturitas 2015; 80: 3-13.
11. Ahmad Khan M, Sarwar AHMG, Rahat R, Ahmed RS, Umar S. Stigmasterol protects rats from collagen induced arthritis by inhibiting proinflammatory cytokines. Int Immunopharmacol 2020; 85: 106642.
12. Yang L, Chen Q, Wang F, Zhang G. Antiosteoporotic compounds from seeds of Cuscutachinensis. J Ethnopharmacol 2011; 135: 553-60.
13. Li SF, Tang JJ, Chen J, et al. Regulation of bone formation by baicalein via the mTORC1 pathway. Drug Des Devel Ther 2015; 9: 5169-83.
14. Chauhan S, Sharma A, Upadhyay NK, et al. In-vitro osteoblast proliferation and in-vivo anti-osteoporotic activity of Bombaxceiba with quantification of Lupeol, gallic acid and β-sitosterol by HPTLC and HPLC. BMC Complement Altern Med 2018; 18: 233.
15. Geng X, Yang L, Zhang C, Qin H, Liang Q. Wogonin inhibits osteoclast differentiation by inhibiting NFATc1 translocation into the nucleus. ExpTher Med 2015; 10: 1066-70.
16. Ma J, Han L, Zhou X, Li Z. Clinical significance of Vitamin-D and other bone turnover markers on bone mineral density in patients with gestational diabetes mellitus. Pak J Med Sci 2022; 38: 23-7
17. Neri AA, Galanis D, Galanos A, Pepe AE, et al. The effect of Ceratonia siliqua supplement on bone mineral density in ovariectomy-induced osteoporosis in rats. In Vivo 2023; 37: 270-85.
18. Yousefzadeh N, Kashfi K, Jeddi S, Ghasemi A. Ovariectomized rat model of osteoporosis: a practical guide. Excli J 2020; 19: 89-107.
19. Jung YK, Kang YM, Han S. Osteoclasts in the inflammatory arthritis: implications for pathologic osteolysis. Immune Netw 2019; 19: e2.
20. Pagani S, Fini M, Giavaresi G, Salamanna F, Borsari V. The active role of osteoporosis in the interaction between osteoblasts and bone metastases. Bone 2015; 79: 176-82.
21. Yang P. Expression prolife of cytokines and chemokines in patients with osteoarthritis and the function of CXCL8 and CXCL11 in the regulation of chondrocytes. Xi'an: The Fourth Military Medical University, 2017: 1-86.
22. Yang Y. The mechanism of osteoblastic CXCL2 in regulation of bone formation and osteoblastic differentiation. Guangzhou: Southern Medical University, 2019: 1-73.
23. Li S, Liu B, Zhang L, Rong L. Amyloid beta peptide is elevated in osteoporotic bone tissues and enhances osteoclast function. Bone 2014; 61: 164-75.
24. Liu L, Wang T, Yang X, et al. MTNR1B loss promotes chordoma recurrence by abrogating melatonin-mediated β-catenin signaling repression. J Pineal Res 2019; 67: e12588.
25. Li Y, Zhou J, Wu Y, et al. Association of osteoporosis with genetic variants of circadian genes in Chinese geriatrics. Osteoporos Int 2016; 27: 1485-92.
26. Mlakar V, Jurkovic Mlakar S, Zupan J, et al. ADRA2A is involved in neuro-endocrine regulation of bone resorption. J Cell Mol Med 2015; 19: 1520-9.
Options
Outlines

/

〈 〉